| The somatic genomic landscape of glioblastoma CW Brennan, RGW Verhaak, A McKenna, B Campos, H Noushmehr, ... cell 155 (2), 462-477, 2013 | 4991 | 2013 |
| Dendritic cells acquire antigens from live cells for cross-presentation to CTL LA Harshyne, SC Watkins, A Gambotto, SM Barratt-Boyes The Journal of Immunology 166 (6), 3717-3723, 2001 | 424 | 2001 |
| A role for class A scavenger receptor in dendritic cell nibbling from live cells LA Harshyne, MI Zimmer, SC Watkins, SM Barratt-Boyes The Journal of Immunology 170 (5), 2302-2309, 2003 | 227 | 2003 |
| Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers M Prosniak, LA Harshyne, DW Andrews, LC Kenyon, K Bedelbaeva, ... Clinical cancer research 19 (14), 3776-3786, 2013 | 198 | 2013 |
| Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines SM Barratt-Boyes, MI Zimmer, LA Harshyne, EM Meyer, SC Watkins, ... The Journal of Immunology 164 (5), 2487-2495, 2000 | 198 | 2000 |
| Prognostic significance of tumor-associated macrophage content in head and neck squamous cell carcinoma: a meta-analysis AT Kumar, A Knops, B Swendseid, U Martinez-Outschoom, L Harshyne, ... Frontiers in oncology 9, 656, 2019 | 111 | 2019 |
| Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients LA Harshyne, BJ Nasca, LC Kenyon, DW Andrews, DC Hooper Neuro-oncology 18 (2), 206-215, 2015 | 96 | 2015 |
| c-Jun NH2-terminal kinase 2α2 promotes the tumorigenicity of human glioblastoma cells J Cui, SY Han, C Wang, W Su, L Harshyne, M Holgado-Madruga, ... Cancer research 66 (20), 10024-10031, 2006 | 90 | 2006 |
| Desmoglein 2 modulates extracellular vesicle release from squamous cell carcinoma keratinocytes AM Overmiller, JA Pierluissi, PJ Wermuth, S Sauma, ... The FASEB Journal 31 (8), 3412, 2017 | 70 | 2017 |
| Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells J Tang, P Flomenberg, L Harshyne, L Kenyon, DW Andrews Clinical Cancer Research 11 (14), 5292-5299, 2005 | 65 | 2005 |
| Exosomal αvβ6 integrin is required for monocyte M2 polarization in prostate cancer H Lu, N Bowler, LA Harshyne, DC Hooper, SR Krishn, S Kurtoglu, ... Matrix Biology 70, 20-35, 2018 | 64 | 2018 |
| Cancer-associated fibroblast density, prognostic characteristics, and recurrence in head and neck squamous cell carcinoma: a meta-analysis AM Knops, A South, U Rodeck, U Martinez-Outschoorn, LA Harshyne, ... Frontiers in Oncology 10, 565306, 2020 | 60 | 2020 |
| Glioblastoma exosomes and IGF-1R/AS-ODN are immunogenic stimuli in a translational research immunotherapy paradigm LA Harshyne, KM Hooper, EG Andrews, BJ Nasca, LC Kenyon, ... Cancer Immunology, Immunotherapy 64, 299-309, 2015 | 58 | 2015 |
| miRNA-and cytokine-associated extracellular vesicles mediate squamous cell carcinomas JP Flemming, BL Hill, MW Haque, J Raad, CS Bonder, LA Harshyne, ... Journal of Extracellular Vesicles 9 (1), 1790159, 2020 | 45 | 2020 |
| Metformin clinical trial in HPV+ and HPV–head and neck squamous cell carcinoma: impact on cancer cell apoptosis and immune infiltrate JM Curry, J Johnson, M Mollaee, P Tassone, D Amin, A Knops, ... Frontiers in Oncology 8, 436, 2018 | 37 | 2018 |
| Phase Ib clinical trial of IGV-001 for patients with newly diagnosed glioblastoma DW Andrews, KD Judy, CB Scott, S Garcia, LA Harshyne, L Kenyon, ... Clinical Cancer Research 27 (7), 1912-1922, 2021 | 35 | 2021 |
| Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma AJ Luginbuhl, JM Johnson, LA Harshyne, AJ Linnenbach, SK Shukla, ... Clinical Cancer Research 28 (5), 915-927, 2022 | 34 | 2022 |
| Discordant responses between primary head and neck tumors and nodal metastases treated with neoadjuvant nivolumab: correlation of radiographic and pathologic treatment effect DJ Merlino, JM Johnson, M Tuluc, S Gargano, R Stapp, L Harshyne Jr, ... Frontiers in oncology 10, 566315, 2020 | 33 | 2020 |
| Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin/gemcitabine (G) in resectable NSCLC. R Zinner, R Axelrod, CC Solomides, S Cowan, B Leiby, AK Bhatia, ... Journal of Clinical Oncology 38 (15_suppl), 9051-9051, 2020 | 33 | 2020 |
| Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy GS Alexander, JD Palmer, M Tuluc, J Lin, AP Dicker, V Bar-Ad, ... Journal of Hematology & Oncology 9, 1-7, 2016 | 25 | 2016 |
Joseph CurryThomas Jefferson University在 jefferson.edu 的电子邮件经过验证
